Company signals · Biotech & Pharma
Merck & Co., Inc.
1 signal in the current window, with MitchelLake's leadership read on each.
Last updated
Market context: This lands while the Talent Market Index reads 105.8 (Hot) — down 2.4 versus the prior month — and Americas signal share is rising (+2.4pts).
Merck & Co., Inc.: 1 signal in the last 90 days — in line with the Biotech & Pharma median of 1 across 24 tracked companies.
Signals at Merck & Co., Inc.
MitchelLake in this thematic
More signals across Biotech & Pharma
Product Launch · Americas
Boehringer Ingelheim →Boehringer Ingelheim reported first-half 2026 sales growth of 16.2% (EUR 15.8 billion), driven by strong U.S. performance including increased demand for JARDIANCE® and successful new product launches.
Product Launch · Americas
Bristol Myers Squibb →Bristol Myers Squibb announced FDA acceptance of its New Drug Application for mezigdomide, an oral CELMoD candidate for relapsed or refractory multiple myeloma combination therapy.
Product Launch · Americas
Neurocrine Biosciences →Neurocrine initiated Phase 2 open-label study of CRENESSITY (crinecerfont) in U.S. infants and toddlers (3 months to under 4 years) with classic congenital adrenal hyperplasia, with concurrent EU trial at target enrollment. Moving toward supplemental U.S. filing to extend indication into pediatric population with no approved therapies.
Product Launch · Americas
Bota Biosciences →Bota Biosciences released Biology Protocol Language (BPL) and BPL-COGEN, a compiler-verified protocol language and generation pipeline for AI-driven biomanufacturing, announced on bioRxiv.
Product Launch · Americas
Thermo Fisher Scientific →Thermo Fisher launched new AI-enabled Orbitrap Tribrid Apex and Orbitrap Excedion mass spectrometers at ASMS Conference, integrating with Olink proteomics and recent AI-focused software acquisitions to strengthen competitive positioning in life sciences tools.
Product Launch · Americas
BridgeBio →BridgeBio submitted NDA to FDA for BBP-418 for LGMD2I/R9 treatment, based on positive Phase 3 FORTIFY trial results showing statistically significant improvements
Intelligence powered by Autonodal ↗